NCT04768673

A Study to Investigate the PK and Safety of CKD-393

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-393 and Co-administration of CKD-501, D759 and H053 Under Fed Condition in Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393

Detailed description

A randomized, open-label, single-dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393 and co-administration of CKD-501, D759 and H053 under fed condition in healthy adults

Conditions

• Type II Diabetes

Interventions

Type	Name	Description
DRUG	CKD-393 formulation I	single, oral administration of 2 tablets under fed condition
DRUG	CKD-393 formulation II	single, oral administration of 2 tablets under fed condition
DRUG	D501, D759, H053	single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Timeline

• Start date: 2021-03-26
• Primary completion: 2021-04-22
• Completion: 2021-04-27
• First posted: 2021-02-24
• Last updated: 2021-08-02

Locations

1 site across 1 country: South Korea